4.2 of 5. Its lupus and kidney programs are extracellular antibodies.
4.1 of 5. Its lupus programs deplete B cells three ways.
4.1 of 5. T-cell engagers deplete B cells, and dapirolizumab blocks CD40L.
4.0 of 5. Gazyva depletes B cells, and fenebrutinib missed SRI-4 in SLE.
3.9 of 5. OM336 and INT2106 both deplete B cells.
3.9 of 5. Benlysta blocks BAFF outside the B cell.